Investor Presentation H1 2023

85 Investor presentation First six months of 2023 Haemophilia is a rare disease with severe unmet medical needs but the market is highly competitive Recombinant haemophilia product sales DKK billion 50 40 30 20 10 0 -0.1% +15% +31% Novo NordiskⓇ 2018 2022 2018 2022 2018 2022 Haemophilia with inhibitors Haemophilia A Haemophilia B Patients¹ ~ 7,000 ~ 185,000 ~ 38,000 NovoSevenⓇ susoctocog alfa² Coagil³ Feiba4 Hemlibra NovoEight® EsperoctⓇ Eloctate Xyntha/Refacto Helixate/Afstyla Benefix Kogenate/Kovaltry/Jivi Advate/Adynovate Hemlibra Alprolix Idelvion RefixiaⓇ/RebinynⓇ Rixubis 1 Total diagnosed patients in segment, WFH annual survey 2021 (numbers may be understated as 118 out of 147 countries responded); 2 Obizur only indicated for acquired haemophilia; 3 Plasma-derived; 4 Part of the Hemlibra sales is used for treatment of haemophilia A patients in 2021 Source: Company reported sales and Evaluate Pharma

View entire presentation